Safety, tolerability and pharmacokinetics of ASC10, a novel oral double prodrug of a broad-spectrum antiviral agent, β-d-N4-hydroxycytidine: results from a randomized, double-blind, placebo-controlled phase 1 study in Chinese healthy subjects.
Jian LiuQingwei ZhaoYou ZhaiXia WuJiejing KaiJie RuanMinglan WuMeijia WuZhuojun ZhouYuemei YanJinzi J WuYunqing QiuPublished in: Expert opinion on investigational drugs (2024)
www.clinicaltrials.gov identifier is NCT05523141.